Researchers have discovered a new molecular pathway which could be used to treat acute myeloid leukaemia (AML)
The team from University of Pennsylvania, USA, used CRISPR gene editing technology screening to identify a therapeutic target known as ZMYND8. It is not a gene mutated in AML, but a protein which ‘reads’ epigenetic changes – chemical changes to the DNA and protein complex known as chromatin. It controls gene activity in AML and allow the continued growth of the cancer, according to the researchers.
Dr Junwei Shi from the University of Pennsylvania and colleagues say that a therapy targeting this new pathway could reduce side effects compared with current chemotherapy approaches. Details were published in the...
12 days ago
Researchers have discovered a new molecular pathway which could be used to treat acute myeloid leukaemia (AML)
The team from University of Pennsylvania, USA, used CRISPR gene editing technology screening to identify a therapeut...
12 days ago
Researchers revealed clues as to how natural mutations that occur during aging can lead to blood cancer in some people.
The joint American and Canadian team say their findings could help to advance the early detection and treat...
12 days ago